| 1 |
32859280 | Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy. | 2021 Sep 7 |
1 |
| 2 |
33169187 | Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed. | 2021 Mar |
1 |
| 3 |
33658858 | The Combination Therapy of Fluorouracil and Oxaliplatin Suppress the Progression of Colon Cancer Through miR-183-5p/SOCS3 Axis and Downregulating PD-L1. | 2021 |
1 |
| 4 |
32489465 | EGFR targeting enhances the efficiency of chemotherapy through inhibiting IRE1α-XBP1s pathway in colorectal cancer cells. | 2020 |
1 |
| 5 |
32622356 | Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature. | 2020 Jul 4 |
1 |
| 6 |
30787271 | ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance. | 2019 Feb 20 |
1 |
| 7 |
31488078 | Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer. | 2019 Sep 5 |
1 |
| 8 |
29368506 | Panitumumab-Conjugated and Platinum-Cored pH-Sensitive Apoferritin Nanocages for Colorectal Cancer-Targeted Therapy. | 2018 Feb 21 |
2 |
| 9 |
29927360 | The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the 'unexplainable'. | 2018 Jul 1 |
2 |
| 10 |
29964008 | Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation. | 2018 Sep 18 |
1 |
| 11 |
30410004 | Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin. | 2018 Nov 8 |
1 |
| 12 |
28283541 | Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab. | 2017 Aug |
1 |
| 13 |
28695301 | Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis. | 2017 Jun |
1 |
| 14 |
26892017 | EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model. | 2016 |
1 |
| 15 |
27246726 | ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. | 2016 May 31 |
1 |
| 16 |
27340349 | Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer. | 2016 Jun 21 |
1 |
| 17 |
28375128 | Combined effects off indomethacin and oxaliplatin on lymph node metastasis related factors in human lung cancerxenografts in nude mice. | 2016 Nov |
4 |
| 18 |
25998052 | Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. | 2015 Jul 28 |
3 |
| 19 |
24403498 | Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer. | 2014 Jan |
2 |
| 20 |
23741067 | Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. | 2013 Aug 1 |
1 |
| 21 |
23822592 | Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody. | 2013 Oct |
2 |
| 22 |
22192364 | Treatment decisions after diagnosis of metastatic colorectal cancer. | 2012 Sep |
1 |
| 23 |
22399593 | Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer. | 2012 Mar |
3 |
| 24 |
20980803 | Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death. | 2011 Jan 1 |
5 |
| 25 |
20001430 | Palliative treatment of unresectable metastatic colorectal cancer. | 2010 Jan |
1 |
| 26 |
20067946 | The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. | 2010 |
2 |
| 27 |
20180626 | Cetuximab and chemoradiation for rectal cancer--is the water getting muddy? | 2010 Apr |
1 |
| 28 |
19581859 | Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin. | 2009 Jun |
1 |
| 29 |
19732064 | Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. | 2009 Sep |
2 |
| 30 |
19915942 | Implications of KRAS mutation status for the treatment of metastatic colorectal cancer. | 2009 Dec |
1 |
| 31 |
19917537 | Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. | 2009 Nov |
1 |
| 32 |
17918158 | Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. | 2008 Jan 15 |
1 |
| 33 |
18845990 | Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. | 2008 Aug |
1 |
| 34 |
19047118 | Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. | 2008 Dec 1 |
2 |
| 35 |
18094427 | Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. | 2007 Dec 15 |
1 |
| 36 |
16320055 | In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. | 2006 Jun |
2 |
| 37 |
16794239 | Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. | 2006 Jun |
1 |
| 38 |
16891475 | Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. | 2006 Jul |
1 |
| 39 |
16062074 | Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. | 2005 Aug |
1 |
| 40 |
16098254 | Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. | 2005 Jul |
1 |
| 41 |
16243822 | Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. | 2005 Oct 15 |
7 |
| 42 |
16336754 | Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway. | 2005 Nov |
1 |
| 43 |
23573555 | New oxaliplatin-based combinations in the treatment of colorectal cancer. | 2003 Nov |
1 |
| 44 |
26680890 | Antitumor Activity of Oxaliplatin, 5-FU and Paclitaxel Given Alone or in Combination with ZD1839 in Human Gastric Carcinoma Cells in vitro. | 2002 Oct |
1 |